A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Melanoma
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Has histologically or cytologically confirmed melanoma. 2) Has unresectable Stage III or Stage IV melanoma. 3) Has progressed after receiving prior PD-1 therapy 4) Has the presence of at least 1 measurable lesion by CT or MRI 5) Received no more than 3 prior regimens

You may not be eligible for this study if the following are true:

1) Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention. 2) Has a known additional malignancy that is progressing or requires active treatment within the past 2 years.